<div>My name is Maxim Izergin. I'm 48 years old, I live in Oslo, Norway, and I've been fighting multiple myeloma — an incurable blood cancer — for 15 years.
</div>
<div><br />
</div>
<div>I have two sons. Markus is 19 and just starting his adult life. Martin is 11 and still needs his dad at every fencing competition, every homework struggle, every bedtime conversation. They are the reason I fight.
</div>
<div><br />
</div>
<div>I was first diagnosed in 2011. Since then, I've gone through every treatment the Norwegian healthcare system could offer — multiple lines of chemotherapy, a stem cell transplant in 2023, and countless hospital stays. Each time, I fought back. Each time, I returned to my family, to my work, to life.
</div>
<div>In March 2026, the cancer returned aggressively. My tumor markers doubled in six weeks. MRI scans showed new lesions spreading through my spine and pelvis. My doctors started emergency bridging chemotherapy to buy time — but time for what?
</div>
<div><br />
</div>
<div><strong>There is a therapy that could save my life: CAR-T cell therapy (Carvykti).</strong> It's a revolutionary one-time treatment where my own immune cells are re-engineered to hunt and destroy cancer cells. It has shown remarkable results in multiple myeloma patients — long-term remissions where other treatments have failed.
</div>
<div><br />
</div>
<div>CAR-T therapy is approved and funded in Sweden, Denmark, Germany, Spain, the UK, and many other European countries. But not in Norway.
</div>
<div><br />
</div>
<div>Norway's drug reimbursement committee (Beslutningsforum) has <strong>rejected Carvykti twice</strong> — in May 2024 and again in March 2026 — citing cost concerns. Meanwhile, the same committee approved an alternative chronic treatment (Blenrep) that costs roughly €880,000 over its expected treatment period — more than double the cost of a single CAR-T infusion. The difference? Blenrep requires hospital visits every three weeks, indefinitely, and causes significant eye toxicity in most patients. CAR-T is given once.
</div>
<div><br />
</div>
<div>Norway's leading myeloma specialist told me directly: "<em>You cannot join the clinical study — it means no treatment until May, and that's too long for you.</em>" The other major hospital confirmed no manufacturing slot is available for approximately two months. My cancer is not waiting.
</div>
<div><br />
</div>
<div><strong>I am a taxpayer.</strong> I run two technology companies — INFOSS and AI Factory — employing people and contributing over 2 million NOK annually in personal and business taxes. I've paid into this system my entire adult life. And now, when I need it most, the system cannot help me.
</div>
<div><br />
</div>
<div>After contacting over 20 hospitals across Europe, I have been accepted for CAR-T therapy at Charité — Universitätsmedizin Berlin, one of Europe's most respected university hospitals. They have reviewed my medical records, prepared an official treatment plan, and are ready to begin as soon as payment is received.
</div>
<div><br />
</div>
<div>The treatment cost is €367,700. This is the lowest quote I received from any hospital in Europe — roughly half of what UK hospitals quoted.
</div>
<div><br />
</div>
<div>What the Money Covers
</div>
<div><br />
</div>
<ul>
<li>CAR-T therapy at Charité Berlin (full treatment) €367,700
</li>
<li>Travel, accommodation, and living costs during treatment (~2–3 months in Berlin)~€40,000
</li>
<li>Post-treatment follow-up and contingency~€42,300
</li>
</ul>
<div><br />
</div>
<div><strong>Total goal €450,000</strong>
</div>
<div><br />
</div>
<div>The treatment process takes several months: cell collection (leukapheresis), 4–6 weeks of cell manufacturing, conditioning chemotherapy, CAR-T infusion, and a critical monitoring period. My wife and I will need to stay in Berlin throughout.
</div>
<div><br />
</div>
<div><strong>Every week matters. </strong>My M-protein levels — a direct measure of cancer activity — went from 9 to 16 to 23 g/L in just six weeks. I am currently on bridging chemotherapy to slow the disease, but this is a temporary measure. The sooner we begin the CAR-T process, the better my chances of a successful outcome.
</div>
<div><br />
</div>
<div><strong>Charité is ready. </strong>The treatment plan is signed. All that stands between me and this therapy is the funding.
</div>
<div><br />
</div>
<div>Any contribution — large or small — brings me closer to treatment. If you cannot donate, sharing this campaign is just as powerful. One share can reach someone who can help.
</div>
<div><br />
</div>
<div><strong>I have never asked for help like this before.</strong> I've always been the one working, building, solving problems. But this is a problem I cannot solve alone.
</div>
<div><br />
</div>
<div>I want to see Martin grow up. I want to be there when Markus builds his future. I want more years with my family.
</div>
<div><br />
</div>
<div>Please help me get there.
</div>
<div><br />
</div>
<div><em>All medical records, hospital correspondence, and the official Charité cost estimate are available for verification. I am committed to full transparency — any funds not used for treatment will be returned to donors or donated to myeloma research.</em>
</div>
<div><br />
</div>

Mila Lilleeng

Ronja Isabel Reinertsen Kile

Anonymous

Pia Sandvik

Danyil Horbachevskyi

Live Grønbekk

Izolda Vlasova

Hedvig Aasgaard

Mikael Kolberg

Daniel Damvall

Jana Leonchanka

Hedda Lie Anholt

Filip Chrzanowski

Help Maxim Get Life-Saving CAR-T Therapy

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

currencyCode

Money Box Donation List Prompt Experiment Audience

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

fund country is US and user language is English (amp15)

Gift cards donation status audience

proCampaignId

p2p legacy startfundraising page

PoDo Incentive audience

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

NPO Upsell without email opt-in

Auto Thanks Feature Audience

International Only

fundId

braze fundraiser group 

Sitewide Banner: CA + en_CA

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

New funds eligible - Video Sharing (PROD) (amp17)

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

US Related Communities

DAF Internal

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

iOS at or above 12.4.0

non-US recurring donors

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

start gfm intl allowed locales

Android v12.12.0 and above

Platform is iOS v11.2.0 and above

NPO upsell education category

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

 Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

Excluded funds - Video Sharing (amp15)

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

checkout headers audience

Users Receiving Braze KYC Validation Failed

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

donationAmount

isDafPay

isEligible

isNPOEmailOptIn

partnerId

isMobile

fundIsLinkedWithMeta

hasSessionDonation

categoryGroup

isCampaignOwner

fundHasInstagramDeepLink

Native 11.3.0 and above

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

NPO email opt-in candidates

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

iOS v12.12.0 and above

Excluded funds - Video Sharing

Fundraiser Without Instagram Deep Link (amp15)

NPO upsell animals category

NPO upsell disaster relief category

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

NPO upsell essential needs category

NPO upsell medical category

userCurrencyCode

Localized Currency

NPO upsell cancer category

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

You’re supporting Help Maxim Get Life-Saving CAR-T Therapy

Your donation will benefit Maxim Izergin

GoFundMe protects your donation